Moderna announced a $1.5 billion financing to support its plans to expand an expected seasonal vaccine franchise and to fund investments in oncology and rare disease programs as it targets break‑even by 2028. The capital infusion is part of a broader restructuring as the company trims less‑promising mRNA programs. Separately, Moderna said it is winding down three clinical mRNA programs, including two investigational infectious‑disease vaccines, as part of its R&D prioritization. The company said savings will be redeployed into higher‑value opportunities and near‑term commercial initiatives. Moderna’s strategy reflects an industry pivot from pandemic‑era breadth to portfolio concentration on sustainable franchises and next‑generation therapeutics.